Legal Representation
Attorney
Richard M. LaBarge
USPTO Deadlines
Application History
47 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 21, 2014 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jul 21, 2014 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Feb 20, 2014 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Feb 20, 2014 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Nov 20, 2013 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 19, 2013 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Nov 14, 2013 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 14, 2013 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Jun 7, 2013 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 6, 2013 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jun 4, 2013 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 4, 2013 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 4, 2013 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Nov 8, 2012 | NOAC | E | CORRECTED NOA E-MAILED | Loading... |
| Nov 8, 2012 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 7, 2012 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| Nov 7, 2012 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Oct 22, 2012 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 22, 2012 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| Oct 22, 2012 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| Oct 22, 2012 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| May 25, 2012 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 24, 2012 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 21, 2012 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 21, 2012 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Dec 9, 2011 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 8, 2011 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Dec 8, 2011 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 29, 2011 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 29, 2011 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 14, 2011 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 19, 2011 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| May 19, 2011 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Apr 19, 2011 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 19, 2011 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 17, 2011 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 17, 2011 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 17, 2011 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 17, 2011 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Mar 15, 2011 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Mar 3, 2011 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 5, 2010 | CPRA | R | PRIORITY ACTION WRITTEN | Loading... |
| Sep 5, 2010 | GPRA | F | PRIORITY ACTION E-MAILED | Loading... |
| Sep 5, 2010 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED | Loading... |
| Aug 29, 2010 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 13, 2010 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 12, 2010 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Human pharmaceuticals for use in the prevention of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders; human pharmaceuticals for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amylodiosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Pharmaceutical research and development; medical and scientific research, namely, conducting clinical trials; medical and scientific research in the fields of treatment for cancer and oncology, and in the fields of treatment of inflammation and autoimmune diseases
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
042